Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Chuanhua Zhao(Chinese PLA General Hospital), Chuan Jin(Guangzhou Medical University), Lin Yang(Alberta Health Services), Zhigang Peng(Guangxi Medical University), Guicheng Wu(Fujian Medical University), Xiaoyong Wei(Ningxia Medical University), Jie Shen(Nanjing Drum Tower Hospital), Ou Jiang(Neijiang Normal University), Kaijian Lei(Second People’s Hospital of Yibin), Cuiping Zheng(Wenzhou Central Hospital), Kehe Chen(The People's Hospital of Guangxi Zhuang Autonomous Region), Jingran Wang(First Hospital of Shijiazhuang), Ying Cheng(Jilin Province Tumor Hospital), Jinfang Zheng(Hainan General Hospital), Yangfeng Du(Central South University), Xianling Liu(Central South University), Bo Zhu(Hebei Medical University), Wei Li(Harbin Medical University), Shaojun Chen(Liuzhou Maternal and Child Health Hospital), Lei Han(Affiliated Hospital of Jining Medical University), Gang Wang(Xijing Hospital), Aimin Li(Hebei Medical University), Zhuang Li, Lianming Cai(Ganzhou People's Hospital), Hailong Liu(Capital Medical University), Jianmin Chen(William & Mary), Zhanxiong Luo(Liuzhou General Hospital), Yuwen Wang(Central South University), Xiuli Liu(Wuhan National Laboratory for Optoelectronics), Ximing Xu(Jiangsu University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Zujiang Yu(First Affiliated Hospital of Zhengzhou University), Sijuan Ding, Aibing Xu(Nantong Tumor Hospital), Yongsheng Yang(First Bethune Hospital of Jilin University), Hongmei Sun(Huanghuai University), Ting Fu(Chongqing University of Technology), Jianbing Wu(Nanchang University), Baocai Xing(Ministry of Education), Weiqing Chen(Chongqing University), Zheng Lu(First Affiliated Hospital of Bengbu Medical College), Zhendong Zheng(General Hospital of Shenyang Military Region), Bangwei Cao(Capital Medical University), Hailan Lin(Fujian Provincial Cancer Hospital), Yanqiao Zhang(Harbin Medical University), Jun Wang(Shandong University), Liangfang Shen(Central South University), Wei Wang(Guangxi University), Yanzhi Bi(University of Chinese Academy of Sciences)
Signal Transduction and Targeted Therapy
August 6, 2025
10.1038/s41392-025-02333-5
Cited by 20

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Ambient Particulate Air Pollution and Daily Mortality in 652 Cities
|New England Journal of Medicine|2019|1.7k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k